MDMA or related drug withdrawal, including MDA

Description

MDMA or related drug withdrawal, including MDA is a clinically significant cluster of symptoms, behaviours and/or physiological features, varying in degree of severity and duration, that occurs upon cessation or reduction of use of MDMA or related drugs in individuals who have developed MDMA or related drug dependence or have used MDMA or related drugs for a prolonged period or in large amounts. Presenting features of MDMA or related drug withdrawal may include fatigue, lethargy, hypersomnia or insomnia, depressed mood, anxiety, irritability, craving, difficulty in concentrating, and appetite disturbance.

Index terms

MDMA or related drug withdrawal, including MDA

Exclusions from above levels

QE11.6 – Hazardous use of MDMA or related drugs
QE62 – Uncomplicated bereavement
QE84 – Acute stress reaction

Sibling codes

6C4C.0 – Episode of harmful use of MDMA or related drugs, including MDA
6C4C.1 – Harmful pattern of use of MDMA or related drugs, including MDA
6C4C.2 – MDMA or related drug dependence, including MDA
6C4C.3 – MDMA or related drug intoxication, including MDA
6C4C.5 – MDMA or related drug-induced delirium, including MDA
6C4C.6 – MDMA or related drug-induced psychotic disorder, including MDA
6C4C.7 – Certain specified MDMA or related drug-induced mental or behavioural disorders, including MDA
6C4C.Y – Other specified disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA]
6C4C.Z – Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA], unspecified

Foundation entity

Allowed postcoordination axes

Part of: 6C4C: Disorders due to use of methylene-dioxymethamphetamine [MDMA] or related drugs, including methylene-dioxyamphetamine [MDA] › 06: Mental, behavioural or neurodevelopmental disorders